FDA Approves HIV Treatments from BMS and J&J
Bristol-Myers Squibb and Johnson & Johnson announced FDA-approval of Evotaz and Prezcobix, combination HIV-1 infection treatments.
On Jan. 29, 2015, Bristol-Myers Squibb (BMS) and Johnson & Johnson (J&J) both announced FDA approval of HIV treatments. BMS announced the approval of Evotaz (atazanavir and cobicistat) when combined with other antiretroviral agents for the treatment of the HIV-1 in adults. On the same day, J&J announced the approval of Prezcobix (darunavir and cobicistat) tablets when combined with other antiretroviral agents.
Both treatments are a once-daily tablet containing a pharmacokinetic enhancer called cobicistat produced by Gilead Sciences, however, Evotaz is combined with the protease inhibitor Reyataz (atazanavir), while Prezcobix uses the protease inhibitor darunavir. The treatments are meant for patients who have not experienced any baseline resistance to the components within the treatments.
Sources:
Bristol-Myers Squibb
Shilpa Medicare Launches ‘Hybrid CDMO’ at DCAT Week 2025
March 17th 2025This model is being positioned by Shilpa as a dual approach that offers comprehensive discovery, clinical, and commercial outsourcing services in addition to commercially ready, “off-the-shelf” novel formulations for b2b licensing.
